CSIMarket
 
Pulse Biosciences Inc   (PLSE)
Other Ticker:  
 
 
Price: $9.8000 $-0.51 -4.947%
Day's High: $10.35 Week Perf: -9.76 %
Day's Low: $ 9.77 30 Day Perf: 6.52 %
Volume (M): 69 52 Wk High: $ 13.62
Volume (M$): $ 673 52 Wk Avg: $6.94
Open: $10.30 52 Wk Low: $2.36



 Market Capitalization (Millions $) 538
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 0

Pulse Biosciences Inc
Pulse Biosciences Inc is a medical technology company that specializes in developing and commercializing innovative therapies using its proprietary Nano-Pulse Stimulation (NPS) technology. This technology is designed to deliver controlled and high-amplitude nanosecond electrical pulses to treat various medical conditions.

The company primarily focuses on dermatology and aesthetic applications, with its flagship product being the CellFX System. The CellFX System utilizes NPS technology to disrupt targeted cells while sparing surrounding healthy tissue, providing a non-thermal, non-thermal ablative treatment option for dermatologic conditions.

Pulse Biosciences Inc aims to revolutionize the field of medical dermatology by providing physicians and patients with a safe, precise, and effective alternative to traditional treatments. The company continues to invest in research and development to explore new therapeutic applications for its NPS technology beyond dermatology, such as in oncology and cardiology.

Overall, Pulse Biosciences Inc is at the forefront of innovating medical technologies, striving to improve patient outcomes and reshape the approach to treating various health conditions.


   Company Address: 3957 Point Eden Way Hayward 94545 CA
   Company Phone Number: 906-4600   Stock Exchange / Ticker: NASDAQ PLSE
   PLSE is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pulse Biosciences Inc

Pulse Biosciences Inc. Reports Crucial Operating Deficit of $-18.025 Million in Q3 2023 Fiscal Period

Pulse Biosciences Inc (PLSE) is a medical equipment and supplies company that recently released its third quarter results for 2023. The company reported an operating deficit of $-11.252 million for the July to September 30 quarter, with no mention of any revenue. However, despite the lack of revenue, experts in the sector have noted that Pulse Biosciences Inc has shown improvement in its operations compared to the same period last year.
In the third quarter of 2022, Pulse Biosciences Inc had an operating deficit of $-18.025 million, indicating that the company has managed to compete more efficiently in the current quarter. The company has been working on developing a business strategy, which seems to have played a role in reducing the diminishing returns in the third quarter of 2023 to $-10.566 million. This is a significant improvement compared to the $-18.039 million reported in the third quarter of 2022.

Pulse Biosciences Inc

Biomedical Tech Giant, Pulse Biosciences Inc, Surpasses Expectations with Major Financial Turnaround in Q2 2023

Financial News Report: Pulse Biosciences Inc Shows Improved Financial Performance
Pulse Biosciences Inc, a leading company in the biomedical technology sector, has reported positive financial results for the interval ending June 30, 2023. The company managed to decrease its loss per share, while also improving its income per share compared to the previous year.
During the April to June 2023 interval, Pulse Biosciences Inc recorded a loss per share of $-0.22, a significant improvement from the loss of $-0.44 per share reported in the same period last year. Additionally, the income per share increased from $-0.26 per share in the preceding financial reporting period.

Pulse Biosciences Inc

Biotech & Pharma Companies Continue Impressive Performance in Q1 2023, Following Year of Similar Achievements

Pulse Biosciences Inc. is a medical technology company that specializes in the development and commercialization of a revolutionary platform technology known as Nano-Pulse Stimulation (NPS). Based in Hayward, California, the company operates in the biotechnology and pharmaceuticals industry. Pulse Biosciences has been working to advance the use of NPS in various medical applications, including the treatment of skin diseases, aesthetic medicine, and oncology.
The company reported a significant improvement in its financial performance for the fiscal period ending March 31, 2023. Pulse Biosciences Inc. was able to decrease its loss per share to $-0.26 compared to $-0.58 a year ago, and earnings per share also improved from $-0.27 per share from the prior quarter. However, the revenue remained unchanged at $0.00 million compared to $0.44 million in the comparable quarter a year ago and sequentially from $-0.01 million. Despite the revenue not improving, the company was able to reduce its net deficit from $-17.273 million in the prior year period to $-9.801 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com